skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

34 Total results for product and free and sample content found

In Vivo

How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

By Dorothee Schramm and Katie von der Weid 27 Nov 2020

effective-relief

The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

Topic Coronavirus Business Strategies Deals

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

By Aidan Fry 27 Nov 2020

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deals

Generics Bulletin

Biocon Biologics Gets True North Investment

By Anju Ghangurde 27 Nov 2020

Biocon_Biologics_Gets_True_North_Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deals Strategy

Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

By Akriti Seth 17 Nov 2020

pfizer biosimilars growth

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

Scrip

2020’s Most Significant Cancer Deals

21 Oct 2020

2020’s Biggest Deals at a Glance

Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.    

Topic Cancer Deals

Pink Sheet, Scrip, In Vivo

Gene Therapy eBook

21 Aug 2020

Gene Therapy eBook

Keep up with advances in the critically important, emerging area of gene therapy. This transformative new category of medicines has the potential to treat more diseases – including complex and rare diseases – with longer-lasting effects than traditional medicines.

Topic Research & Development Deals

In Vivo

In Vivo Deal Making Article Pack

15 Apr 2020

In Vivo Deal Making Article Pack

Gain a view into the market gaps, opportunities, and trends in biopharma with a look at deal-making from In Vivo. Examine how deal-making has impacted the industry and shifted market dynamics and learn how you can use knowledge of these trends to inform your own strategies.

Generics Bulletin

Sun Finds US ‘Challenging’

By Penelope MacRae 17 Feb 2020

Flags_USA_India

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic Deal trends

Scrip

J.P. Morgan Conference Updates

By Mandy Jackson 22 Jan 2020

JP_Morgan_Notebook_Day_1

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: